LAUSR

Background Whether patients with acute heart failure syndrome (AHFS) need to reach the target dose of renin-angiotensin-system (RAS) blocker and beta-blocker to obtain a benefit in terms of clinical outcome remain uncertain. We aimed to evaluate the dose response relationship of RAS blocker and beta-blocker using the Korean Acute Heart Failure (KorAHF) registry. Methods The KorAHF registry is a prospective observational multicenter cohort study of AHFS in Korea. We investigated the relationship between usage and doses of RAS blocker and beta-blocker with 180 days overall survival outcome in these patients. Results Among 2,829 patients who discharged alive with reduced ejection fraction (≤ 40%), RAS blocker was prescribed in 2,197 patients (77.7%) and beta-blocker 1,623 patients (57.4%). 180 day all-cause mortality was 13.2% (N=374). Usage of both RAS blocker (p Conclusion While usage of RAS blocker or beta-blocker showed clear benefit in terms of clinical outcome, dose response relationship was evident only in RAS blockers but not in beta-blockers. Further research is needed to understand the dose response relationship of these medications and potential application of individualized dose-titration regimen.